View in EDS

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.

Saved in:

Bibliographic Details
Title:	Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.
Authors:	Voskaridou E; Thalassemia and Sickle Cell Disease Center, 'Laiko' General Hospital, Athens, Greece., Ntanasis-Stathopoulos I; Department of Clinical Therapeutics and., Papaefstathiou A; Endocrine Unit, Second Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Center, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; and., Christoulas D; Department of Hematology and., Dimopoulou M; Thalassemia and Sickle Cell Disease Center, 'Laiko' General Hospital, Athens, Greece., Repa K; Thalassemia and Sickle Cell Disease Center, 'Laiko' General Hospital, Athens, Greece., Papatheodorou A; Department of Biomedical Research, 251 General Air-Force Hospital, Athens, Greece., Peppa M; Endocrine Unit, Second Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Center, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; and., Terpos E; Department of Clinical Therapeutics and.
Source:	Blood advances [Blood Adv] 2018 Nov 13; Vol. 2 (21), pp. 2837-2847.
Publication Type:	Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2473-9537
DOI:	10.1182/bloodadvances.2018023085